New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
07:46 EDTRDHL, SLXPSalix, RedHill Biopharma announce exclusive license agreement for RHB-106
Salix Pharmaceuticals (SLXP) and RedHill Biopharma (RDHL) announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments. Financial terms of the transaction include an upfront payment of $7M and $5M in subsequent milestone payments to RedHill. Salix also has agreed to pay RedHill tiered royalties on net sales, ranging from low single-digit up to low double-digits. Under the worldwide license agreement, the parties also agreed on potential strategic collaboration with regard to certain other Salix products in specific territories.
News For SLXP;RDHL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
07:09 EDTRDHLRedHill Biopharma receives notice of allowance for two U.S. patents for RHB-104
RedHill Biopharma announced that it has received two notices of allowance from the United States Patent and Trademark Office regarding its patent application numbers 13/722,395 and 14/271,758 covering RHB-104. RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties, currently undergoing a first Phase III study for Crohn's disease and a Phase IIa study for multiple sclerosis.
June 29, 2015
07:08 EDTRDHLRedHill Biopharma initiates Phase I/II study of ABC294640
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use